https://seekingalpha.com/news/4153575-roche-biogen-post-late-stage-win-for-kidney-drug
Thursday, September 26, 2024
Roche, Biogen post late-stage win for kidney drug
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) unit Genentech announced Thursday that Gazyva, a lymphoma therapy it co-develops with Biogen (NASDAQ:BIIB), reached the primary endpoint in a Phase 3 trial for patients with lupus nephritis, a potentially fatal kidney disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.